CGEN earnings: next report 2026-08-03, real EPS beat/miss history, analyst consensus Buy, P/E 6.60. Updated 2026-07-23.
Compugen (CGEN) Research Hub
Compugen (CGEN) trades on NASDAQ, IL in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.47 USD (-0.40%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 6.60, market cap 0.23B. This hub links to the full technical, earnings and options research available for CGEN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IL |
| Last close | 2.47 USD (-0.40%) |
| 52-week range | 1.98 USD – 2.94 USD |
| Trend regime | Range |
| 14-day RSI | 52.8 (Neutral) |
| Trailing P/E | 6.60 |
| Market cap | 0.23B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-03 |
Available research for CGEN
Covered Call on CGEN: how it works, illustrative setup around the real 2.47 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CGEN: how it works, illustrative setup around the real 2.47 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CGEN: how it works, illustrative setup around the real 2.47 USD price, max profit/loss, breakeven and when to use it. Educational.
CGEN technical analysis: range, last 2.47 USD, RSI 52.8, 52w range 1.98 USD–2.94 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CGEN in?
Compugen (CGEN) is classified under Healthcare (Biotechnology), listed on NASDAQ, IL.
Is CGEN in an uptrend or downtrend?
As of 2026-09-11, CGEN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CGEN's trailing P/E ratio?
CGEN's trailing P/E is 6.60, with a market cap of 0.23B. See the earnings research page for full valuation detail.
When does CGEN next report earnings?
CGEN is next scheduled to report earnings on 2026-08-03, with a consensus EPS estimate of -0.07 USD.